-
Fierce Biotech3 months ago
AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and...
-
Fierce Biotech3 months ago
After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer
After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic...
-
Uncategorized3 months agoMHRA to offer early review of non-animal data
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in...
-
Fierce Biotech3 months ago
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to...
-
Uncategorized3 months agoSygnature Discovery appoints new Head of In Vivo Pharmacology
CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology. Back has 20 years of in vivo pharmacology experience across academia and industry, including...
-
Uncategorized3 months ago
Takeda clears path to FDA with phase 3 data on $4B psoriasis bet
Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share...
-
Uncategorized3 months agoRadspherin receives patent protection in China
The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients. Radspherin, developed by biotechnology company...
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: ‘We’re on the inside now’: Meet the man building a political empire behind RFK Jr.
WASHINGTON — In the past three years, Robert F. Kennedy Jr. has had a dramatic ascent, rocketing from the contrarian fringe to the center of the American health...
-
STAT News – Biotech3 months agoAs political pressure mounts, medical school accreditor drops requirement to teach about health equity
The leading medical school accreditation body in the U.S. has removed language from its standards that had required schools it validates to teach about health inequities. ...
-
STAT News – Biotech3 months agoDecades after Vietnam War, research links Agent Orange exposure to MDS blood cancer
Decades after the Vietnam War, hematologist-oncologist Mikkael Sekeres began seeing veterans in his clinic with myelodysplastic syndromes, a group of blood cancers known as MDS. Many...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
